Biomarkers - Resources

Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.

Events

In-Person & Online Events

Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.

Online Activities

Our Monthly Science Exchanges and Webinars keep you connected to the conversation.

All Online Activities
Community

Speakers

Attracting leading experts & the brightest minds in the industry to educate, inform and excite our attendees.

More Info

Sponsors

Our range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

More Info

Media Partners

We work with leading journal publications on reciprocal marketing arrangements.

More Info
Services

In-Person Services

At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.

More Info

Digital Marketing Services

Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.

More Info
Resources

Browse All Resources

The latest in biomarkers research, from development and diagnostics to precision medicine.

All Biomarkers Resources

Latest Resources

Imaging Starts Using Brand New Radiotracer from Nuclidium

21/10/24 - The radiotracer is the first part of Nuclidium’s proposed ‘theranostic pipeline’ which aims to diagnose, stage, and then treat prostate cancer.

01/10/24 - GHR Foundation Commits $15m to C2N Diagnostics for Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease

06/09/24 - Study Analyses Predictive Biomarkers for COVID-19 ICU Patient Mortality
Contact
Our Brands

Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.

Oxford Global

Precision Medicine

Discovery & Development

NextGen Biomed

A New Golden Age for Target Identification: Accessing the Novel Druggable Space with Discovery Proteomics

On-demand webinar presented by Mo Jain, MD, PhD, Founder and CEO, Sapient and Jonathan Usuka, PhD, MBA Chief Business Officer, Sapient

Watch Now

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.

Read Now

Content Type

Categories

Keywords

Biomarker Discovery & Development

Optimer - Drug Conjugates

Biomarker Discovery & Development

Optimer - Enabled Small Molecule Detection and Analysis

Biomarker Discovery & Development

Optimer Diagnostic Reagent COVID-19 Datapack

Biomarker Discovery & Development

Supelco - BIOshell Peptide Mapping Trastuzumab UHPLC-MS

Biomarker Discovery & Development

Supelco - Supel Carbon N-Glycan Human IgG

Biomarker Discovery & Development

The Optimer Discovery Platform

Biomarker Discovery & Development

Whole Exome Sequencing (WES) Data Generation Service

Clinical Development

Surrogate Biomarkers in NASH and Liver Cirrhosis: Qualifying for Clinical Trial Validation and Legislative Success

Highly involved treatment scenarios and prognostics are required to properly assess best-practice approaches for investigating issues posed by NASH and liver cirrhosis. Surrogate biomarkers present a less invasive approach to assessing these outcomes.

Diagnostic Development

Emergency Use Authorization Issued by FDA for Mpox Virus DNA Test

EUAs exist under FDA regulation to improve the availability of medical countermeasures, such as vaccines and diagnostic tests, during public health emergencies. With future pandemics a tangible possibility, further EUAs for other PCR tests and vaccines are all but certain.

Genomic Biomarkers

Clinical Biomarker Trends to Watch in 2023

The identification of novel clinical biomarkers is set to continue, with further research and investment in fields such as next-gen sequencing and miRNA targeting.

Clinical Development

Keytruda sees Trial Success in Treating Endometrial Cancer Patients

The immunotherapeutic was successfully trialled in patients with endometrial cancer, the results of which Merck said it would discuss with regulatory authorities.

Clinical Development

Eli Lilly Focus on Phase III Trial for Alzheimer’s Treatment Following FDA Fast Lane Setback

The FDA ‘specifically requested’ data from at least 100 patients who received a minimum 12 months’ treatment of Lilly’s drug donanemab before the approval process could progress further.

Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Next